Cardiovascular complications of COVID-19 vaccines: A review of case-report and case-series studies

The new coronavirus is known as "Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV2)", responsible for COVID-19 disease originated in China in 2019 and rapidly became a pandemic. Soon after vaccination was started and till now, 38 types of vaccines are approved in different countries1-3. The development of an effective vaccine against the SARS-CoV-2 virus that causes COVID-19 disease has been proven to be a vital tool in controlling the high pandemic's spread and its enormous effects4. Multiple coronavirus vaccines are currently being developed, including the mRNA-1273 (Moderna), mRNA vaccines BNT162b2 (Pfizer-BioNTech/Comirnaty), adenoviral vector vaccine: Ad26.COV2.S (Johnson& Johnson/Janssen), AZD1222 (Oxford-AstraZeneca/Covidshield) and the inactivated vaccines: CoronaVac (Sinovac Bio (Sputnik V) and WIBP / BBIBP-CorV COVID-19 vaccine (Sinopharm)5.
Source: Heart and Lung - Category: Intensive Care Authors: Source Type: research